• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

35

CATEGORIES

  • 16
  • 14
  • 10
  • 5
  • 4
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

20
29
33
63

PUBLISHED

0
3
12
63

PRODUCT TYPE

49
14

Search "Santaris Pharma A/S" returned 63 results.

PRODUCT TITLE
Santaris Pharma A/S - Product Pipeline Review - H2 2011 Santaris Pharma A/S - Product Pipeline Review - H2 2011 - Product Thumbnail Image

Santaris Pharma A/S - Product Pipeline Review - H2 2011

Santaris Pharma A/S – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Santaris...

November 2011
FROM
Santaris Pharma A S - Product Pipeline Review - Q4 2010 Santaris Pharma A S - Product Pipeline Review - Q4 2010 - Product Thumbnail Image

Santaris Pharma A S - Product Pipeline Review - Q4 2010

Santaris Pharma A S – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s...

November 2010
FROM

Santaris Pharma A S - Product Pipeline Review - Q4 2010

Santaris Pharma A S – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s...

November 2010
FROM
PCSK9 Inhibitors - The hot new approach to lower cholesterol PCSK9 Inhibitors - The hot new approach to lower cholesterol - Product Thumbnail Image

PCSK9 Inhibitors - The hot new approach to lower cholesterol

Several companies are actively pursuing a new strategy to lower cholesterol: the inhibition of the PCSK9 gene/enzyme This enzyme speeds the degradation of LDL receptors Thus its inhibition should preserve...

October 2012
FROM

Global MicroRNA Market 2012-2016

The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research...

September 2013
FROM

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma

“Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma” provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where...

February 2010
FROM
Competitor Analysis: Targeted Therapy of Hepatitis C Competitor Analysis: Targeted Therapy of Hepatitis C - Product Thumbnail Image

Competitor Analysis: Targeted Therapy of Hepatitis C

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C)...

August 2011
FROM
Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships - Product Thumbnail Image

Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships

A major new 3-volume report from Espicom featuring: - An examination of trends and advances in the three major drug delivery sectors - Unique sales forecasts to 2020 for key products - Critical analyses...

September 2011
FROM
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech Discovery Stage Partnering Terms and Agreements in Pharma and Biotech - Product Thumbnail Image

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements...

February 2014
FROM
Santaris Pharma A/S-Therapeutic Competitors Report Santaris Pharma A/S-Therapeutic Competitors Report - Product Thumbnail Image

Santaris Pharma A/S-Therapeutic Competitors Report

Santaris Pharma A/S-Therapeutic Competitors Report Report includes a business summary, tabular representation of the number and percentage of products in each therapeutic indication, all company products...

March 2011
FROM

Gynecological Cancer - Pipeline Review, H1 2013

Gynecological Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

May 2013
FROM
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities - Product Thumbnail Image

Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities

This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines It provides opinions & market projections to: - assess the commercial potential of RNAi-based...

July 2009
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? - Product Thumbnail Image

Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global melanoma pipeline and presents actionable analysis which allows you to discover: - Where the competition is; Which...

June 2013
FROM
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others - Product Thumbnail Image

Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development Find out whether you are number one, two or further down the ladder...

August 2012
FROM

Hypercholesterolemia - Pipeline Review, H2 2013

Hypercholesterolemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

September 2013
FROM
AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review

AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review Summary AVI BioPharma, Inc. (AVI) is a biopharmaceutical company engaged in the discovery and development of RNA based drugs...

September 2011
FROM

Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2012

Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2012" provides data on the...

October 2012
FROM
Epigenetics and MicroRNA Diagnostics/Therapeutics 2008 Epigenetics and MicroRNA Diagnostics/Therapeutics 2008 - Product Thumbnail Image

Epigenetics and MicroRNA Diagnostics/Therapeutics 2008

This is the latest Epigenetics and MicroRNA Diagnostics/Therapeutics Market Report This report presents an up-to-date and thorough analysis of the Epigenetics Marketplace based upon our continuing industry...

May 2008
FROM
The Future of RNAi Therapeutics: Drug Pipelines and Prospects The Future of RNAi Therapeutics: Drug Pipelines and Prospects - Product Thumbnail Image

The Future of RNAi Therapeutics: Drug Pipelines and Prospects

"The total RNAi therapy market is estimated to value $580m by 2012 This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled in this...

September 2008
FROM
Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics - Product Thumbnail Image

Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics

The study of epigenetics - changes in gene expression that occur without a change in a cell’s DNA code – is becoming increasingly important as scientists explore how internal and external factors trigger...

November 2009
FROM
Loading Indicator